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350Early Elevation of C-Reactive Protein Correlates with
Severe Infection and Nonrelapse Mortality in Children
Undergoing Allogeneic Stem Cell Transplantation
Jennifer L. McNeer,1 Morris Kletzel,2,3 Alfred Rademaker,2 Kavita Alford,3 Kathleen O’Day,4
Colleen Schaefer,2,3 Reggie Duerst,2,3 David A. Jacobsohn2,3C-reactive protein (CRP) is an acute phase reactant that is a reliable marker of systemic inflammation and has
been associated with increased morbidity and mortality following hematopoietic stem cell transplantation
(HSCT) in adults. In this study, we evaluated whether early elevations of CRP were associated with various
complications and nonrelapse mortality following HSCT in pediatric patients. Seventy pediatric patients
had CRP levels drawn at regular time points during the first week following their transplants. Patients
were followed for 100 days following transplant, and transplant-related complications were documented.
Patients who subsequently developed severe infections had higher median CRP values than those without
severe infections (median 8.03 mg/dL versus 1.64 mg/dL, P 5 .0008) as did those who suffered nonrelapse
mortality compared with those who did not (12.6 mg/dL versus 2.44 mg/dL, P5 .02). These findings suggest
that elevated CRP values may be useful as a marker of individual pediatric patients with a higher risk for
treatment-related morbidity and mortality.
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Hematopoietic stem cell transplantation (HSCT) is
used successfully in children to treat a variety of disor-
ders including hematologicmalignancies, bonemarrow
failure syndromes, solid tumors, metabolic disorders,
and immunodeficiencies. However, complications
such as infections, graft-versus-host disease (GVHD),
sinusoidal obstruction syndrome (SOS), and graft
failure often occur with HSCT. Despite known clinical
risk factors, including advanced disease status of the
recipient, comorbid illnesses, HLA-mismatch, use of
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6/j.bbmt.2009.10.036older donor age, and female donor sex [1,2], predicting
which patients will develop major complications re-
mains difficult, and treatment-related mortality re-
mains high, with overall survival (OS) ranging from
35% to 50% for umbilical cord blood (UCB) or unre-
lated donor transplants and 50% to 70% following
HSCT from HLA-identical siblings [3-6].
C-reactive protein (CRP) is an acute phase reactant
primarily produced by hepatocytes and regulated by
the cytokine interleukin-6 (IL-6) in response to tissue
damage, infection, and inflammation. It has been
shown to be a reliablemarker of systemic inflammation
[7,8]. In vitro it binds to bacterial phospholipids as
well as other ligands, thereby activating the classical
complement pathway through interaction with C1q.
Conversely, CRP activation can inhibit the generation
of the C5-C9 membrane attack complex through its
interaction with factor H [7]. It also elicits responses
from phagocytic cells through interactions with FcgRI
and FcgRII, and has a number of other pro-inflamma-
tory activities mediated through various adhesion
molecules and interleukins [7]. Taken as a whole,
CRP aids with host defense, while limiting excessive
inflammation.
Studies in adult patients have demonstrated that
elevated CRP may predict transplant complications.
In various studies, elevated CRP has been associated
with infections [9], the development of acute GVHD
Table 1. Baseline Patient Characteristics (N 5 70)
Characteristic N (%)/Median (Range)
Age 10 years (3 months to 20 years)
Sex
Male 39 (56%)
Female 31 (44%)
Diagnosis
Malignant 50 (71%)
ALL 22 (31%)
AML 16 (23%)
CML 4 (6%)
BAL 1 (1%)
NHL 5 (7%)
HL 2 (3%)
Nonmalignant 20 (29%)
Conditioning
Full intensity 37 (53%)
Reduced intensity 33 (47%)
Cell source
HLA-matched related 32 (46%)
Alternative donor 38 (54%)
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[10-14]. In pediatric studies of transplant patients, ele-
vated CRP has been associated with the development
of sepsis [15], and has been suggested as a component
of a risk score for stem cell transplant patients requir-
ing admission to pediatric intensive care units [16,17].
However, the prognostic value of CRP has not been
adequately studied in the pediatric HSCT population.
Given the differences between pediatric and adult
HSCT patients, such as different stem cell sources
(eg, more unrelated CB transplants) and different indi-
cations for HSCT (eg, more nonmalignant diseases),
the pattern of CRP response may be different than in
adults. This study was designed to determine the sig-
nificance of an early elevation of CRP and its relation
to adverse outcomes following allogeneic HSCT in
pediatric patients.Mismatched related (HLA 7:8) 1
Haploidentical (HLA 4:8) 1
Unrelated cord blood
HLA 4:6 7
HLA 3:6 3
Adult unrelated
HLA 8:8 12
HLA 7:8 11
HLA 6:8 3
CRP (mg/dL) 3.47 (0.1-27.7)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; CML, chronic myelogenous leukemia; BAL, biphenotypic
acute leukemia; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma;
HLA, human leukocyte antigen; CRP, C-reactive protein.MATERIALS AND METHODS
Patients
Seventy pediatric patients (median age, 10 years;
range: 3 months to 20 years) undergoing allogeneic
HSCT at Children’s Memorial Hospital in Chicago,
IL, were enrolled between February 2003 and February
2008 (Table 1). This study was approved by the institu-
tional review board of Children’s Memorial Hospital,
Chicago, IL, andwas registered atwww.clinicaltrials.gov
(NCT00179868). Consent was obtained from patients
18 years and older and the parents of all patients\18
years of age; assent was obtained from patients aged 12
to17years.Thecohort included31femalesand39males;
65 were undergoing first HSCT, whereas 5 were under-
going their second HSCT. There were 50 patients with
malignant diseases, and 20 patients with nonmalignant
diseases. Stem cell sources included 32 HLA-matched
related donors (21 peripheral blood [PBSC], 9 bone
marrow, 2 sibling UCBs), 26 unrelated adult donors
(PBSC), 10 unrelated UCB, and 2 mismatched-related
or haploidentical-related donors (PBSC).Timing of CRP Levels and Outcome
Determination
Blood (2.5 mL) in a serum tube for CRP levels was
drawn on days 0 and 7. Inpatient samples were drawn at
4 a.m. with routine daily labs. Outpatient samples were
drawn upon a patient’s arrival in the ambulatory stem
cell clinic that day. Samples were run on the same day
using the CRP turbidimetric assay (normal range
0-0.8 mg/dL) on theDXC600 Instrument by Beckman
Coulter, Inc. (Fullerton, CA). Information regarding
the development of complications was recorded for
the first 100 days following transplant. Physicians and
nurses caring for the patients were blinded to the
CRP results.Definitions of Censored Complications
Complications of interest included severe infec-
tions (defined as documented Gram-negative bacterial
infections, proven or probable fungal infections, or
Gram-positive bacterial infections associated with
signs of sepsis such as hypotension, tachycardia, poor
perfusion/urine output, respiratory distress, or mental
status changes), grades II-IV aGVHD, grades III-IV
aGVHD, and NRM.Transplantation Regimens
Thirty-seven patients underwent myeloablative
(MA) conditioning regimens. MA conditioning regi-
mens were total body irradiation (TBI) 1200 cGy
with cyclophosphamide (Cy; 60 mg/kg/day intrave-
nously for 2 days) and VP-16 (1000 mg/m2/day intra-
venously for 1 dose) or busulfan (Bu; 1 mg/kg/
dose every 6 hours intravenously for 16 doses, targeted
to an area under the curve (AUC) between 800 and
1200 mmol*min/dose)/Bu (60 mg/kg/day intrave-
nously for 2 days) with VP-16 (1000 mg/m2/day
intravenously for 1 dose).
A total of 33 patients underwent reduced-intensity
conditioning (RIC) regimens using fludarabine (Flu) as
previously described [18]. These patients received Bu
(targeted to an AUC of 4000 mmol*min/day  2 days)
352 Biol Blood Marrow Transplant 16:350-357, 2010J. L. McNeer et al.with or without rabbit antithymocyte globulin (ATG)
or extracorporeal photophoresis (ECP) [19]. One pa-
tient with Fanconi Anemia received a single fraction
of 200 cGy of TBI after Flu as part of a clinical study
on which hewas enrolled, and 1 patient with hemopha-
gocytic lymphohistiocytosis (HLH) received etopo-
side, ATG, and thiotepa with Flu for her first of
2 transplants.
Molecular high-resolution DNA typing was per-
formed for both class I and II antigens for all recipients
and donors. For UCB transplants, a 4:6 antigen match
or greater was required at HLA-A, HLA-B, and HLA-
DR, with a cell dose .3.5  107 total nucleated cell
(TNC)/kg of recipient weight. For unrelated donor
transplants, a 7:8 or greater antigen and a 6:8 or greater
allele match was required atHLA-A, HLA-B,HLA-C,
and HLA-DR.
Hematopoietic stem cells were neither T cell-de-
pleted nor purged. aGVHD prophylaxis for MA,
matched related sibling transplants consisted of cyclo-
sporine (CsA) every 12 hours starting on day 21, and
short-course methotrexate (MTX) on days 1, 3, and
6 as previously described [20]. Patients who underwent
MAregimens forUCBandunrelated donor transplants
received continuous infusion CsA, short-course MTX,
and equine/rabbit ATG as previously described [20].
All recipients of RIC regimens received CSA and my-
cophenolate mofetil (MMF) for GVHD prophylaxis
as described [18].
Supportive care has been described previously
[18,20]. Briefly, all patients undergoing myeloablative
conditioning were cared for in positive pressureHEPA
filtered rooms, whereas those conditioned with re-
duced-intensity regimens were treated as outpatients
in the ambulatory stem cell clinic. Antimicrobial pro-
phylaxis included fluconazole, acyclovir, and pentami-
dine. Intravenous immunoglobulin (IVIG) or
cytomegalovirus (CMV) immune globulin (in the
case of a CMV-positive patient or donor) was given
until 6 months after HSCT if the IgG level was
\400. Patients who underwent MA conditioning re-
ceived granulocyte-colony stimulating factor (G-
CSF) at night starting on day 17 until the absolute
neutrophil count was .500 for 3 consecutive days. In
all cases, the day 7 CRP was drawn before G-CSF ad-
ministration. Broad spectrum antibiotics were started
empirically for febrile neutropenia or for nonneutro-
penic fevers with cardiovascular instability. Nonneu-
tropenic patients (generally those who underwent
reduced-intensity conditioning [RIC]) who were fe-
brile but cardiovascularly stable were treated empiri-
cally with single daily ceftriaxone and daily
monitoring in the ambulatory stem cell transplant
clinic. Initial treatment for clinical grade II or greater
aGVHD was with methylprednisolone, with addi-
tional immunosuppressive therapy such as ECP, inflix-
imab, daclizumab, or another calcineurin inhibitor asneeded [20]. aGVHD was graded weekly according
to the Keystone criteria [21].
Neutrophil recovery was defined as achievement of
a peripheral neutrophil count.500 cells/mL for 3 con-
secutive days. Platelet recovery was defined as a platelet
count above 20,000/mL without transfusions for at
least 7 days. Donor chimerism was determined every
7 days until full donor chimerism was achieved. This
was assessed using a polymerase chain reaction-based
variable-number tandem-repeat (VNTR) analysis of
peripheral blood leukocytes [22].
Statistical Analysis
Primary outcomes included severe infection (de-
fined as Gram-negative bacterial infections, fungal
infections, or Gram-positive bacterial infections
associated with signs of sepsis), grades II-IV aGVHD,
grades III-IV aGVHD, andNRM, all occurring within
the first 100 days following transplant. We also evalu-
ated the associations between diagnosis (categorized
as nonmalignant versus malignant), conditioning regi-
men (categorized as RIC versus MA), cell source (cate-
gorized as matched-related versus alternative donor),
and donor sex and CRP values. For our analyses, we
used either the day 0 or day 7 CRP value for each
patient, whichever was higher. Because of the skewed
nature of CRP values, nonparametric Wilcoxon rank
sum tests were used to compare CRP values between
the dichotomous categories of pretransplant risk factors
and the outcomes of interest. Hazard ratios were calcu-
lated for time to outcome data using proportional
hazards regression.
Receiver operating characteristic (ROC) analysis
was used to generate CRP values that provided optimal
combinations of sensitivity and specificity for our sig-
nificant outcomes. From these values positive predic-
tive values (PPV) and negative predictive values
(NPV) were calculated, Kaplan-Meier curves were
used to generate cumulative incidence of NRM in
the first 100 days following transplant, and these
were compared between CRP categories using the
log rank test. Statistical analyses were done using
SAS statistical software version 9.2 (SAS Institute,
Cary, NC).RESULTS
We examined whether there was a correlation be-
tween certain pretransplant risk factors and an elevated
CRP. We found that of the pretransplant risk factors
evaluated, diagnosis and conditioning regimen were
significantly related to CRP value (Table 2). Median
CRP values for the 50 patients with (71%) and 20
without (29%) malignancy were 4.37 mg/dL (range:
0.1-27.7) and 1.29 mg/dL (range: 0.31-24), respec-
tively (P 5 .027). Thirty-seven patients (53%) who
Table 2. Association between Pretransplant Risk Factors and
CRP Values
Risk Factor (N) P-Value
Median CRP
(mg/dL) (Range)
All patients (70) — 3.47 (0.1-27.7)
Diagnosis .027
Malignant (50) 4.37 (0.1-27.7)
Nonmalignant (20) 1.29 (0.31-24.0)
Conditioning .003
Myeloablative (37) 6.45 (0.39-24.6)
Reduced Intensity (33) 1.30 (0.10-27.7)
Cell source .26
Sibling (32) 3.80 (0.10-24.6)
Alternative donor (38) 2.00 (0.21-27.7)
Donor sex .99
Male (42) 2.95 (0.1-27.7)
Female (28) 3.81 (0.32-24.6)
CRP indicates C-reactive protein.
P-values by Wilcoxon rank sum test.
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Figure 1. Scatter plot with medians of maximum day 0-7 CRP by
severe infection or NRM.
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CRP of 6.45 mg/dL (range: 0.39-24.6), whereas the
33 (47%) who underwent an RIC transplant had a me-
dian CRP of 1.3 mg/dL (range: 0.1-27.7) (P 5 .003).
Cell source was not related to CRP, with median
values of 3.8 mg/dL (range: 0.1-24.6) and 2 mg/dL
(range: 0.21-27.7) in 32 patients (46%) receiving cells
from an HLA-identical sibling versus 38 patients
(54%) who were transplanted using an alternative do-
nor, respectively (P 5 .26). Finally, donor sex had no
significant effect on CRP value, with patients who
had a male donor having a median CRP of 2.95 mg/
dL, and those with female donors having a median
value of 3.81 mg/dL (P 5 .99).
We also determined whether the CRP value had
a correlation with our primary posttransplant out-
comes of interest. Of the primary outcomes, patients
with either severe infection or NRM had significantly
higher CRP values than their counterparts without
these outcomes (Table 3 and Figure 1). There were
27 patients (39%) who developed severe infections,
with a median onset of infection on day 117 (range:Table 3. Association between CRP Values and Outcomes
Outcome (N) P-Value
Median CRP
(mg/dL) (Range)
Severe infection .0008
Yes (27) 8.03 (0.1-27.7)
No (43) 1.64 (0.21-24.6)
Acute GVHD .25
0-I (51) 3.06 (0.21-27.7)
II-IV (19) 5.71 (0.1-24.6)
Acute GVHD .52
0-II (59) 3.24 (0.21-27.7)
III-IV (11) 11.30 (0.1-23.2)
NRM .02
Yes (9) 12.6 (0.77-27.7)
No (61) 2.44 (0.1-24.6)
GVHD indicates acute graft-versus-host disease; CRP, C-reactive
protein; NRM yes/no, occurrence or not of nonrelapse mortality within
the first 100 days following transplant.
P-values by Wilcoxon rank sum test.day 29 to day 91). Those with severe infections had
a median CRP value of 8.03 mg/dL (range: 0.1-27.7),
compared to a median of 1.64 mg/dL (range: 0.21-
24.6) in those who did not develop severe infections
(P 5 .0008). Gram-negative bacteria accounted for 16
of the infections, fungal infection for 12 (7 confirmed
bybiopsy, culture, or galactomanan assay, and5deemed
probable based on clinical picture and imaging studies)
andGram-positive bacteria/sepsis for 3 (total infections
exceed 27 because of multiple infections in some pa-
tients). Also significant was the association between
CRP andNRM.Those that died (9, 13%) had amedian
CRP of 12.6 mg/dL (range: 0.77-27.7), compared to
a median CRP of 2.44 mg/dL (range: 0.1-24.6) in those
not sufferingNRM (P5 .02). Causes of death included
respiratory failure (2), multiorgan system failure (5),
pericardial effusion (1), and pulmonary hemorrhage
(1). Four of the patients who died of NRM had infec-
tions at the time of death: 2 with fungal infections and
2 with CMV infections.
We saw a nonstatistically significant trend toward
an increased CRP with the development of aGVHD.
The 19 patients (27%) that developed grade II-IV
aGVHD had a median CRP of 5.71 mg/dL (range:
0.1-24.6), whereas the 51 patients (73%) with grade
0-I aGVHD had a median CRP of 3.06 mg/dL (range:
0.21-27.7) (P 5 .25). There were 11 patients (16%)
who had aGVHD greater than grade II, and again,
there was not a significant association with CRP in
this group compared to patients with grade II or less
aGVHD (median CRP 11.30 mg/dL versus 3.24 mg/
dL, P 5 .52).
Using ROC analysis to generate clinically mean-
ingful CRP values, we identified a cutoff CRP value
of 4.35mg/dL as being 70% sensitive and 72% specific
for the development of severe infection in the first 100
days posttransplant (Figure 2A). The PPV and NPV
for infection associated with this CRP value are 61%
and 79%, respectively (pretest prevalence 5 39%).
Similar analysis generated a cutoff CRP value of 7.05
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Figure 2. (A) ROC curve for the outcome of severe infection. The AUC is 0.742. The arrow indicates a CRP of 4.35 mg/dL, which corresponds to
a sensitivity of 70% and specificity of 72% for severe infection. (B) ROC curve for the outcome of NRM. The AUC is 0.742. The arrow indicates
a CRP of 7.05 mg/dL, which corresponds to a sensitivity of 72% and specificity of 78% for NRM.
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come of NRM (Figure 2B). The PPV associated with
this CRP value is 29%, with an NPV of 96% for
NRM (pretest prevalence5 13%). The cumulative in-
cidence of NRM in those patients with CRP .7.05
mg/dL was 29% (95% confidence interval [CI] 11%-
47%), whereas in those with CRP\ 7.05 mg/dL, it
was 4% (0%-8%) (Figure 3, P 5 .003).
We then used Cox proportional hazards to gener-
ate a univariate analysis of various prognostic factors
on our outcomes of interest (Table 4) to determine if
elevated CRP itself was a marker of increased risk of
severe infection or NRM, or if it was a surrogate
marker for increased risk, particularly in patients
with malignant diseases or those treated with MA
conditioning regimens. Despite results of the earlier
Wilcoxon rank sum analysis, which revealed statisti-
cally significant associations between both disease
and conditioning regimen and elevated median CRP
values, we did not find a significant association
between these risk factors and our outcomes of inter-
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Figure 3. Cumulative incidence of NRM according to maximum CRP
during days 0-7 of HSCT.those with malignant disease or MA conditioning
were 1.26 (P 5 .60) and 1.17 (P 5 .69), respectively.
For NRM, the HRs in patients with malignant disease
or MA conditioning were 1.46 (P 5 .64) and 0.70
(P 5 .59), respectively. However, using CRP as a di-
chotomous variable, with a cutoff of 7.05 mg/dL as
identified by ROC analysis, we found a significant as-
sociation between CRP .7.05 mg/dL and the devel-
opment of both severe infections (HR 2.99, P 5 .01)
and NRM (HR 7.55, P 5 .01). Additionally, there
was a trend toward significance for grades III-IV
aGVHD with an HR of 2.78 (P 5 .09) when compar-
ing patients with a CRP .7.05 mg/dL to those with
a CRP\7.05 mg/dL. There was not a statistically sig-
nificant association with grade II-IV aGVHD (data
not shown). Because CRP was the only factor signifi-
cantly associated with the outcomes of interest, a mul-
tivariate analysis was not performed.DISCUSSION
Although there have been major improvements in
outcomes following HSCT over the years, there con-
tinue to be considerable posttransplant complications
that lead to significant morbidity and mortality.
Despite the use of prophylactic antibiotics, immune
suppression, and improvements in supportive care,
patients continue to succumb to infections, GVHD,
and various complications that result in NRM.
Although general guidelines exist to help identify at-
risk patients, recognizing risk factors in individual
patients will help to improve outcomes further.
There has been considerable interest focused on
the identification of inflammatory biomarkers that
may predict the presence of complications following
HSCT. These markers include CRP, IL-6, IL-8, in-
terleukin-2-receptor-alpha (IL-2Ra), procalcitonin,
and tumor necrosis factor-a (TNF-a) among others
[9-14,23-26]. There is evidence in adult populations,
that elevated CRP values may predict adverse
Table 4. Univariate Analysis of Risk Factors and Adverse Outcomes
Infection aGVHD grade III/IV NRM
Factor HR (95%CI) P HR (95%CI) P HR (95% CI) P
Age >10 years 1.34 (0.63-2.86) .45 1.85 (0.54-6.34) .32 3.73 (0.77-17.95) .10
Patient sex 1.02 (0.48-2.17) .97 1.50 (0.46-4.91) .51 0.61 (0.15-2.45) .49
Donor sex 1.26 (0.59-2.68) .56 0.79 (0.23-2.69) .70 0.72 (0.18-2.88) .64
Diagnosis 1.26 (0.53-2.98) .60 0.79 (0.23-2.70) .70 1.46 (0.30-7.04) .64
Conditioning 1.17 (0.55-2.50) .69 1.28 (0.39-4.19) .69 0.70 (0.19-2.60) .59
Cell Source 1.12 (0.52-2.39) .77 1.53 (0.45-5.21) .50 3.11 (0.65-14.97) .16
CRP >7.05 mg/dL 2.99 (1.39-6.42) .01 2.78 (0.85-9.12) .09 7.55 (1.57-36.37) .01
aGVHD indicates acute graft-versus-host disease; NRM, nonrelapse mortality; CRP, C-reactive protein.
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ment of aGVHD and NRM [10-13], and elevated
CRP has been identified as a sensitive marker of bac-
teremia in patients with febrile neutropenia [23].
Elevated CRP has also been shown to be a marker
of true infection in pediatric patients [27,28] and as
a way to discriminate between bacteremia and contam-
inated cultures [29]. Very few studies, however, have
been specific to pediatric HSCT populations, espe-
cially for identifying early elevations of biomarkers
that predict future complications. Kitko et al. [25] eval-
uated early (day 17) elevations of tumor necrosis
factor-receptor-1 (TNFR1) in children undergoing
HSCT, given that TNF-a is a known mediator of
GVHD.They found that themagnitude of TNFR1 el-
evation at day 7 compared to baseline TNFR1 values
correlated with GVHD severity and that a high ratio
of day 7 TNFR1 versus baseline correlated with worse
overall survival. In an earlier study, Sauer et al. [15] ex-
amined procalcitonin, CRP, and endotoxin in pediatric
HSCTpatients and found bothCRP and procalcitonin
values to be significantly elevated in those patients with
sepsis compared to those without, whereas serum pro-
calcitonin correlated with the severity of the septic
episodes. More investigation is needed in the pediatric
population, given their unique indications for trans-
plant and sources of stem cells for transplantation (eg,
greater use of UCB).
In this study, we evaluated the association between
several known pretransplant risk factors, CRP values,
and adverseHSCToutcomes, specifically in a pediatric
population. Our patient population was quite hetero-
geneous, with a variety of underlying diagnoses and
a number of different conditioning regimens utilized.
Of the pretransplant risk factors examined, we found
a significant association between both underlying di-
agnosis and conditioning regimen and elevated CRP
values in the first 7 days following HSCT. A history
of high-risk malignancy and the need for prior chemo-
therapy to induce remission, followed closely thereaf-
ter with the intense conditioning regimen undertaken
in MA HSCT leads to more tissue damage, theoreti-
cally weakening the body’s physical barriers to
infections. An elevated CRP following intense condi-
tioning may indicate that this severe tissue damageand inflammation has occurred, increasing the vulner-
ability to subsequent severe infections and susceptibil-
ity to multiorgan system failure. This vulnerability
may be because of inflammatory damage to the gastro-
intestinal barrier, allowing gut flora to enter the blood-
stream in patients who are especially susceptible given
their compromised immune systems. However, al-
though as a group those patients with malignant dis-
ease or MA conditioning had a significantly higher
median CRP compared to their counterparts, this
did not translate directly into significant associations
between either disease or conditioning and our out-
comes of interest. This indicates that elevated CRP is
not merely a surrogate marker for adverse outcomes
because of a history of these risk factors.
On the other hand, using a CRP value that was
identified as relatively sensitive and specific for NRM,
we did find that having a CRP higher than that value
was significantly related to a patient’s development of
severe infections and/or NRM.Themedian day for di-
agnosis of infection in our cohort was day117, indicat-
ing that elevations of CRP within the first week of
HSCT may predict later infections. Although several
of our patients who died of NRM had infections at
the time of their death, the causes of death were not
deemed to be solely because of infectious causes. Fi-
nally, although there was certainly a trend, there was
not a statistically significant association between CRP
and the development of grades II-IV aGVHD, in con-
trast to similar studies conducted in adult populations
[10,12,13]. The cumulative incidences of grades II-IV
and grades III-IV aGVHD in our cohort were quite
low, however, at only 27% and 17%, respectively,
and therefore our study may have been too small to de-
tect a significant association.CRP levels have been sug-
gested as a measure of general health status [14], and
those patients with higher levels may have worse health
to begin with, leading to a propensity for infections as
well as other causes ofNRM.So although there is an as-
sociation between certain prognostic factors (disease or
conditioning regimen) and an elevated CRP, it is an
elevated CRP itself, which seems to be a marker for
certain adverse outcomes in pediatric HSCT patients.
Given the desire to improve quality of life for
children undergoing HSCT and to minimize
356 Biol Blood Marrow Transplant 16:350-357, 2010J. L. McNeer et al.hospitalization days whenever possible, we are caring
for a growing number of transplant patients in the out-
patient setting. Although low CRP values are not sen-
sitive or specific enough to make initial decisions to
treat or not to treat febrile or otherwise ill children fol-
lowing HSCT, low CRP values early on may allow
physicians to shorten the duration of antibiotics in pa-
tients without proven infections and may be reassuring
for a particular patient’s long-term survival following
HSCT. Conversely, high CRP values should not be
used empirically to start therapies, but may identify
children who would benefit from closer monitoring
and potentially broader therapy when infection is sus-
pected. In our study, CRP values did not have suffi-
ciently high PPVs or NPVs to definitively predict
outcomes of severe infections or NRM, except seem-
ingly for an NPV of 96% against NRM for patients
with a maximum CRP\7.05 mg/dL in the first week
of HSCT. However, data continues to emerge regard-
ing numerous biomarkers and cytokines and their asso-
ciation with adverse outcomes following HSCT
[10,11,14,15,25]. Perhaps early CRP values could be
useful as part of an algorithm to more effectively tailor
interventions to individual patients, while more effi-
ciently utilizing resources.
Our study is limited by the fact that we evaluated
a very heterogeneous population with a wide range
of underlying disorders, conditioning regimens and
cell sources. This does not allow for in-depth analysis
within particular populations, but may improve the
generalizability of the results. Furthermore, although
many of our outcomes were objective, there is some
subjectivity as to what was considered severe infec-
tions, in particular, the diagnosis of sepsis associated
with Gram-positive infections and the diagnosis of
fungal infections in some of our patients. In regard
to fungal infections, culture or biopsy data was ob-
tained whenever possible, but some patients were too
ill to undergo biopsies. For these patients, imaging
studies were reviewed by several clinicians and radiol-
ogists, and follow-up studies were performed to best
determine the true likelihood of fungal infections.
Finally, immunoglobulin is known to have anti-
inflammatory activity [30], but only some of our pa-
tients required IVIG therapy, and for various lengths
of time. The IVIG infusions that these patients
received following HSCT may have ameliorated their
inflammatory states, possibly altering whether or not
they suffered adverse outcomes.
This study demonstrates the predictive value of
early elevations of CRP in pediatric patients as an indi-
cator of treatment-related morbidity and mortality in
the first 100 days following HSCT. Although not
strong enough to be used alone to guide treatment, it
is certainly possible that CRP could be used with other
biomarkers to develop a risk score for various adverse
outcomes. Future studies looking at CRP in combina-tion with markers such as IL-6, IL-8, procalcitonin,
and TNF-a [11,15,25,31] in pediatric patients would
be valuable in developing such tools.ACKNOWLEDGMENTS
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